Oragenics (NYSEAMERICAN:OGEN) Posts Quarterly Earnings Results

Oragenics (NYSEAMERICAN:OGEN) released its quarterly earnings data on Friday. The company reported ($1.96) earnings per share for the quarter, FiscalAI reports.

Oragenics Stock Performance

OGEN traded up $0.00 during midday trading on Friday, reaching $1.12. 67,999 shares of the company were exchanged, compared to its average volume of 281,778. The company has a market cap of $4.61 million, a price-to-earnings ratio of -0.05 and a beta of 0.83. Oragenics has a one year low of $1.01 and a one year high of $18.90. The company’s fifty day moving average price is $1.25 and its 200 day moving average price is $2.53.

Institutional Investors Weigh In On Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Clear Street LLC acquired a new position in shares of Oragenics, Inc. (NYSEAMERICAN:OGEN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 70,619 shares of the company’s stock, valued at approximately $270,000. Clear Street LLC owned about 8.58% of Oragenics at the end of the most recent reporting period. 18.71% of the stock is owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.